MAPT and Alzheimer disease: Specifically, we observed that AD-tau–injected APPPS1:E4 male mice had significantly longer sleep bout lengths during the dark phase (1800–2100 and 0000–0300 hours, respectively) than did female mice after 7 weeks of SD treatment compared with the first week of SD (Figure 9D).